Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research and Development Contracts (N01)
Project #
N01AI005062-009
Application #
2294602
Study Section
Project Start
1990-02-01
Project End
1995-01-31
Budget Start
1992-10-06
Budget End
1993-01-31
Support Year
Fiscal Year
1993
Total Cost
Indirect Cost

  Institution

Name
Vanderbilt University Medical Center
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
004413456
City
Nashville
State
TN
Country
United States
Zip Code
37212

  Publications

Gilbert, P B; Chiu, Y-L; Allen, M et al. (2003) Long-term safety analysis of preventive HIV-1 vaccines evaluated in AIDS vaccine evaluation group NIAID-sponsored Phase I and II clinical trials. Vaccine 21:2933-47
Keefer, M C; Graham, B S; McElrath, M J et al. (1996) Safety and immunogenicity of Env 2-3, a human immunodeficiency virus type 1 candidate vaccine, in combination with a novel adjuvant, MTP-PE/MF59. NIAID AIDS Vaccine Evaluation Group. AIDS Res Hum Retroviruses 12:683-93
Graham, B S; Keefer, M C; McElrath, M J et al. (1996) Safety and immunogenicity of a candidate HIV-1 vaccine in healthy adults: recombinant glycoprotein (rgp) 120. A randomized, double-blind trial. NIAID AIDS Vaccine Evaluation Group. Ann Intern Med 125:270-9
Graham, B S; Wright, P F (1995) Candidate AIDS vaccines. N Engl J Med 333:1331-9
Schwartz, D H; Mazumdar, A; Winston, S et al. (1995) Utility of various commercially available human immunodeficiency virus (HIV) antibody diagnostic kits for use in conjunction with efficacy trials of HIV-1 vaccines. Clin Diagn Lab Immunol 2:268-71
Graham, B S (1994) Serological responses to candidate AIDS vaccines. AIDS Res Hum Retroviruses 10 Suppl 2:S145-8
Keefer, M C; Graham, B S; Belshe, R B et al. (1994) Studies of high doses of a human immunodeficiency virus type 1 recombinant glycoprotein 160 candidate vaccine in HIV type 1-seronegative humans. The AIDS Vaccine Clinical Trials Network. AIDS Res Hum Retroviruses 10:1713-23
Pincus, S H; Messer, K G; Schwartz, D H et al. (1993) Differences in the antibody response to human immunodeficiency virus-1 envelope glycoprotein (gp160) in infected laboratory workers and vaccinees. J Clin Invest 91:1987-96
Montefiori, D C; Graham, B S; Kliks, S et al. (1992) Serum antibodies to HIV-1 in recombinant vaccinia virus recipients boosted with purified recombinant gp160. NIAID AIDS Vaccine Clinical Trials Network. J Clin Immunol 12:429-39
Montefiori, D C; Zhou, J; Shaff, D I (1992) CD4-independent binding of HIV-1 to the B lymphocyte receptor CR2 (CD21) in the presence of complement and antibody. Clin Exp Immunol 90:383-9

Showing the most recent 10 out of 11 publications